The acute or chronic drug treatments for different neurodegenerative and psychiatric
disorders are challenging from several aspects. The low bioavailability and limited brain …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Abstract According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is
the 6th primary cause of death in the USA, which affects nearly 5.5 million people. In the …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

Since the application of chitosan magnetic cationic microspheres in brain drug delivery by
Gallo in 1993, chitosan has been extensively studied in brain drug delivery. As the only …

Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating
applications, directly targeting the central nervous system, bypassing the blood brain barrier …

There is an obvious need for efficient and safe nasal absorption enhancers for the
development of therapeutically efficacious nasal products for small hydrophilic drugs …

Alzheimer's disease is a neurological disorder that results in cognitive and behavioral
impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs …